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Abstract
Aims/hypothesis Dicarbonyl compounds are formed as
byproducts of glycolysis and are keymediators of diabetic com-
plications. However, evidence of postprandial α-dicarbonyl
formation in humans is lacking, and interventions to reduce
α-dicarbonyls have not yet been investigated. Therefore, we
investigated postprandial α-dicarbonyl levels in obese women
without and with type 2 diabetes. Furthermore, we evaluated
whether a diet very low in energy (very low calorie diet
[VLCD]) or Roux-en-Y gastric bypass (RYGB) reduces
α-dicarbonyl stress in obese women with type 2 diabetes.
Methods In lean (n=12) and obese womenwithout (n=27) or
with type 2 diabetes (n=27), we measured the α-dicarbonyls,
methylglyoxal (MGO), glyoxal (GO) and 3-deoxyglucosone
(3-DG), and glucose in fasting and postprandial plasma
samples obtained during a mixed meal test. Obese women
with type 2 diabetes underwent either a VLCD or RYGB.
Three weeks after the intervention, individuals underwent a
second mixed meal test.
Results Obese women with type 2 diabetes had higher fasting
and particularly higher postprandial plasma α-dicarbonyl
levels, compared with those without diabetes. After three
weeks of a VLCD, postprandial α-dicarbonyl levels in diabetic
womenwere significantly reduced (AUCMGO−14%,GO−16%,
3-DG −25%), mainly through reduction of fasting plasma
α-dicarbonyls (MGO −13%, GO −13%, 3-DG −33%). Similar
results were found after RYGB.
Conclusions/interpretation This study shows that type 2
diabetes is characterised by increased fasting and postprandial
plasma α-dicarbonyl stress, which can be reduced by
improving glucose metabolism through a VLCD or RYGB.
These data highlight the potential to reduce reactive
α-dicarbonyls in obese individuals with type 2 diabetes.
Trial registration: ClinicalTrials.gov NCT01167959
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Postprandial glucose excursions are a detrimental factor in
diabetic complications [1]. An important mechanism for
postprandial glucose peaks contributing to increased risk
of diabetic complications may be the formation of
α-dicarbonyls, which have been linked to a range of
detrimental effects on cellular function [2].
We recently showed that individuals with type 2 diabetes
had higher plasma levels of the α-dicarbonyls methylglyoxal
(MGO), glyoxal (GO) and 3-deoxyglucosone (3-DG), after a
glucose load [3]. These highly reactiveα-dicarbonyls are main-
ly formed as glycolytic intermediates during glucose metabo-
lism and rapidly interact with protein residues [2]. Importantly,
α-dicarbonyl stress has been linked to diabetic complications
[2]. However, whether type 2 diabetes is associated with higher
plasma α-dicarbonyls after a meal is unknown.
Weight loss interventions, particularly energy restriction
and bariatric surgery, have been linked to improved glucose
metabolism and reduction of diabetic complications [4].
Interestingly, beneficial effects of energy restriction and
bariatric surgery on insulin resistance seem to occur rapidly
[5]. Thus, it is likely that α-dicarbonyls will be rapidly
reduced by these interventions.
Therefore, we investigated whether type 2 diabetes is
associated with higher fasting and postprandial plasma
α-dicarbonyl levels compared with lean and obese women
with normal glucose tolerance (NGT) and whether a diet very
low in energy or Roux-en-Y gastric bypass (RYGB) reduces
plasma α-dicarbonyl levels in obese women with type 2
diabetes.
Methods
Study design and population The research design of this
study has been described previously [5]. In short, we included
obese women with NGT (n=27) or type 2 diabetes (n=27)
who were eligible for dietary or surgical treatment. Age-
matched, healthy women with normal BMI (<25 kg/m2;
n=12) were included as controls for baseline comparisons.
NGT obese individuals underwent either gastric banding
(GB, n=11) or RYGB (n=16). Obese individuals with type
2 diabetes either underwent a diet very low in energy (very
low calorie diet, VLCD, n=12) or RYGB (n=15). All women
were characterised at baseline and obese women were
additionally characterised 3 weeks after weight loss
intervention. After discontinuing glucose-lowering
medication for 48 h and overnight fasting (≥10 h), participants
underwent a liquid mixed meal test (MMT) which consisted
of 266 ml (1673.6 kJ [400 kcal]) Nutridrink (Nutricia,
Zoetermeer, the Netherlands) [5]. The study protocol (clinical
trial registration no. NCT01167959) was approved by the
medical ethical committee of the Leiden University Medical
Center and all participants provided written informed consent.
All analyses were performed blind.
Biochemical measurements α-Dicarbonyl levels in EDTA
plasma samples were measured as described previously [6].
Serum glucose levels and insulin resistance were assessed as
described previously [5].
Calculation of area under the curve The AUC for
α-dicarbonyls and glucose measured during the MMT was
Table 1 Baseline characteristics
of the study population Characteristic Lean (n= 12) Obese NGT (n = 27) Obese T2DM (n= 27)
Age (years) 49.2 ± 6.2 47.7 ± 6.4 51.0 ± 7.1
Weight (kg) 64.4 ± 7.2 124.3 ± 11.7*** 117.2 ± 17.1
BMI (kg/m2) 21.7 ± 1.6 43.8 ± 3.2*** 42.0 ± 5.5
Waist (cm) 78.0 ± 6.0 122.3 ± 9.2*** 123.2 ± 11.0
Fat mass (%) 35.5 ± 2.4 56.3 ± 2.2*** 55.7 ± 4.4
HbA1c (mmol/mol) 31.9 ± 2.5 36.1 ± 7.8 49.6 ± 12.0
†††
HbA1c (%) 5.1 ± 0.2 5.5 ± 0.7 6.7 ± 1.1
†††
Triacylglycerols (mmol/l) 1.0 ± 0.3 1.4 ± 0.6 1.8 ± 0.7†
NEFA (mmol/l) 0.9 ± 0.3 1.0 ± 0.4 1.2 ± 0.3
Total cholesterol (mmol/l) 5.0 ± 0.9 4.6 ± 1.0 4.4 ± 0.8
HDL cholesterol (mmol/l) 1.7 ± 0.3 1.1 ± 0.3*** 1.1 ± 0.3
LDL cholesterol (mmol/l) 2.9 ± 0.9 2.9 ± 0.9 2.5 ± 0.6
HOMA-IR 0.3 ± 0.1 3.2 ± 2.3** 5.4 ± 3.6†
Data are presented as means ± SD
Differences between the groups were tested using a one-way ANOVAwith Bonferroni correction
**p< 0.01 and ***p < 0.001 for lean vs obese NGT individuals.
† p< 0.05 and ††† p< 0.001 for obese NGT individuals vs obese individuals with type 2 diabetes (T2DM)
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calculated using the trapezoidal rule, where fasting levels were
subtracted from each individual data point to specify
postprandial excursions (incremental AUC, iAUC
[nmol/l × min for α-dicarbonyls and mmol/l × min for
glucose]).
Statistical analysis Baseline levels of α-dicarbonyls and
glucose were compared using one-way ANOVA with
Bonferroni correction. Two-way repeated measures ANOVA
with Bonferroni correction was used to compare the three
groups at baseline during the MMT. Adjustment for plasma
glucose levels was performed with one-way ANCOVA with
Bonferroni correction. Paired two-sided sample t tests were
used to compare α-dicarbonyl and glucose levels before and
after weight loss interventions. Data are expressed as means
(SEM), unless otherwise stated. All statistical analyses were
performed with IBM SPSS Statistics Software, version 20
(IBM Corporation, Armonk, NY, USA) and a two-sided
p value of <0.05 was considered statistically significant.
Results
Baseline characteristics of the study population are reported in
Table 1 [5].
Fasting plasma MGO levels are higher in obese NGT
women Fasting plasma MGO levels were higher in obese
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Fig. 1 Baseline plasma levels of α-dicarbonyls and glucose before and
during a mixed meal test. Plasma levels during the MMTof (a) MGO, (c)
GO, (e) 3-DG and (g) glucose and iAUC, as calculated from the MMTof
(b) MGO, (d) GO, (f) 3-DG and (h) glucose. Data are shown as means
(SEM). Triangles, lean, n = 12; squares, obese NGT, n= 27; circles, obese
type 2 diabetic individuals, n = 27. Differences in postprandial curves
during the mixed meal between the groups were tested with repeated-
measures two-way ANOVA with Bonferroni correction. Differences in
the iAUCs of MGO, GO, 3-DG and glucose between the groups were
tested with one-way ANOVA with Bonferroni correction. *p < 0.05,
**p < 0.01 and ***p < 0.001 compared with lean individuals and
†††p< 0.001 compared with obese NGT individuals
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Fig. 2 Plasma levels of α-dicarbonyls and glucose in obese individuals
with type 2 diabetes after 3 weeks of a VLCD. Plasma levels during the
MMT of (a) MGO, (c) GO, (e) 3-DG and (g) glucose and iAUC, as
calculated from theMMT, of (b)MGO, (d) GO, (f) 3-DG and (h) glucose.
Data are shown as means (SEM). Black circles, obese type 2 diabetes
individuals before the VLCD; open circles, obese type 2 diabetes
individuals 3 weeks after the VLCD, n= 12. Differences in fasting levels
and the iAUCs of MGO, GO, 3-DG and glucose were tested with paired
two-sided samples t tests. *p< 0.05 compared with baseline
Diabetologia (2016) 59:2013–2017 2015
electronic supplementary material [ESM] Table 1, p<0.05),
which remained significant after adjustment for glucose
(ESM Table 1). None of the other fasting α-dicarbonyls were
increased in obese NGT individuals (ESM Table 1).
Furthermore, iAUCs of all plasma α-dicarbonyls and glucose
did not differ between lean and obese NGT individuals
(Fig. 1b,d,f,h).
Fasting and postprandial α-dicarbonyl stress is higher in
obese women with type 2 diabetes When we compared
obese individuals with NGT and those with type 2 diabetes
at baseline, we found significantly higher fasting plasma
levels ofα-dicarbonyls (ESMTable 1, p<0.01 for all) in those
with type 2 diabetes. Particularly, the postprandial iAUCs of
MGO, 3-DG and glucose were higher (p<0.01 for all) in
obese individuals with type 2 diabetes compared with obese
NGT individuals (Fig. 1b,f,h). We observed a similar, yet
non-significant difference between obese NGT and type 2
diabetic individuals for the iAUC of GO (Fig. 1d). After
adjustment for glucose, all significant differences between
obese individuals without and with type 2 diabetes were
attenuated (ESM Table 1).
Fasting plasma MGO levels are reduced by RYGB in
obese NGT women within 3 weeks In obese NGT
individuals, we observed reduced fasting MGO levels after
RYGB (p < 0.05), but no significant reduction in other
α-dicarbonyls (ESM Fig. 1).Weight loss through GB in obese
NGT individuals did not lead to changes in α-dicarbonyl
stress (ESM Fig. 2).
A VLCD and RYGB reduce fasting and postprandial
plasma α-dicarbonyl stress in obese women with type 2
diabetes In obese type 2 diabetic individuals, postprandial
α-dicarbonyls and glucose levels were decreased after 3
weeks of a VLCD (Fig. 2a,c,e,g). Indeed, the total load of
α-dicarbonyls and glucose after a meal, as reflected by the
AUC, was substantially decreased by the VLCD (data not
shown, p<0.05 for all). This effect was mostly attributable
to decreased fasting α-dicarbonyls (MGO and 3-DG,
p<0.05 for both), as the postprandialα-dicarbonyl excursions
(iAUC) after a meal were similar before and after the VLCD
(Fig. 2b,d,f). Fasting plasma GO levels did not change signif-
icantly after 3 weeks of the VLCD, but a non-significant
(p=0.11) reduction was observed. Comparable findings re-
garding the effect on postprandial α-dicarbonyl stress were
found 3 weeks after RYGB (ESM Fig. 3).
Discussion
This study shows that obese individuals with type 2 diabetes
have higher fasting and particularly higher postprandial
plasma α-dicarbonyl levels than individuals without diabetes.
Moreover, VLCD and RYGB reduced plasma α-dicarbonyl
stress in obese type 2 diabetic individuals, mainly through
reduction of fasting plasma α-dicarbonyls.
In obese NGT individuals, we found higher fasting
plasma MGO levels compared with lean individuals,
but we observed no further postprandial increase.
Interestingly, these increased fasting MGO levels were
reduced by RYGB. The elevated fasting MGO levels in
obese individuals compared with healthy individuals
remained significant after adjustment for glucose.
Therefore, other pathways may contribute to increased
MGO formation in obese NGT individuals. In contrast, fasting
and postprandial plasma levels of the other α-dicarbonyls
were not affected by the presence of obesity.
Our current findings on increased postprandial
α-dicarbonyl stress in type 2 diabetes, together with similar
findings in type 1 diabetes [7], are in line with our previous
work, in which we demonstrated increased α-dicarbonyl
stress in type 2 diabetic individuals after an oral glucose
load [3]. Therefore, it is likely that the increased α-
dicarbonyl levels after a meal result from increased
postprandial glucose levels. Furthermore, the possible
role of other substrates for α-dicarbonyl formation, such
as reduced lipid oxidation and reactive oxygen species
(ROS) cannot be excluded. ROS are known to increase
postprandially in type 2 diabetes [8] and, therefore, re-
duction of ROS by weight loss could also be
responsible for lower postprandial MGO stress, but this
phenomenon deserves further investigation. Additionally,
a VLCD may reduce MGO via induction of nuclear
factor (erythroid-derived 2)-like 2 (Nrf2), an inducer of
the MGO-detoxifying enzyme glyoxalase-1 [9].
Our current findings are of potential clinical impor-
tance, since α-dicarbonyls have been identified as po-
tential key mediators of diabetic complications. Of the
three major α-dicarbonyls, MGO is the most potent
glycating agent [2]. MGO seems to play a crucial role
in the development of diabetic complications, particular-
ly via induction of endothelial dysfunction. Therefore,
excursions in MGO at the fasting and postprandial level
in type 2 diabetic individuals are a potential target for
prevention and treatment of diabetic complications. For
example, quenching α-dicarbonyls may be possible with
the vitamin B6 analogue, pyridoxamine [10]. Furthermore,
MGO may be reduced via induction of glyoxalase-1, using
inducers of Nrf2 [9].
This is the first study that describes increased postprandial
α-dicarbonyl stress in obese type 2 diabetic individuals, and
its reduction by weight loss. Future work should investigate
whether a VLCD and RYBG achieve health improvements
and lower cardiovascular risk through reduced α-dicarbonyl
stress. A limitation of this study was that we could not include
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a control group that remained weight-stable. Nevertheless, we
report on two distinct interventions that aimed to induce
weight loss, showing comparable results. Another limitation
was that we lacked statistical power to investigate mediating
factors through which α-dicarbonyl levels were improved by
VLCD and RYGB.Additionally, we investigated women only
in the current study, but we have no basis to assume that our
results would be different in men. Furthermore, our study does
not reveal which tissues contribute to the plasma pool of
α-dicarbonyls. Although we hypothesise that plasma
α-dicarbonyls are derived from insulin-independent cells
which are in close contact with blood, such as endothelial cells
and erythrocytes, animal studies are needed to fully address
this issue.
In conclusion, we demonstrated increased postprandial
α-dicarbonyl stress in obese individuals with type 2 diabetes,
which can be reduced by a VLCD or RYGB. These data
highlight the potential to reduce α-dicarbonyls as a target to
prevent or delay development of complications in obese type
2 diabetic individuals.
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